JP2018537128A5 - - Google Patents

Download PDF

Info

Publication number
JP2018537128A5
JP2018537128A5 JP2018548246A JP2018548246A JP2018537128A5 JP 2018537128 A5 JP2018537128 A5 JP 2018537128A5 JP 2018548246 A JP2018548246 A JP 2018548246A JP 2018548246 A JP2018548246 A JP 2018548246A JP 2018537128 A5 JP2018537128 A5 JP 2018537128A5
Authority
JP
Japan
Prior art keywords
individual
nras
kras
cell
multiple myeloma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018548246A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537128A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2016/051191 external-priority patent/WO2017091865A1/en
Publication of JP2018537128A publication Critical patent/JP2018537128A/ja
Publication of JP2018537128A5 publication Critical patent/JP2018537128A5/ja
Priority to JP2021165655A priority Critical patent/JP2022000059A/ja
Pending legal-status Critical Current

Links

JP2018548246A 2015-12-03 2016-12-02 骨髄腫の治療または進行のモニタリング Pending JP2018537128A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021165655A JP2022000059A (ja) 2015-12-03 2021-10-07 骨髄腫の治療または進行のモニタリング

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2015905013 2015-12-03
AU2015905013A AU2015905013A0 (en) 2015-12-03 Monitoring treatment or progression of myeloma
AU2016903019 2016-08-01
AU2016903019A AU2016903019A0 (en) 2016-08-01 Monitoring treatment or progression of myeloma (2)
PCT/AU2016/051191 WO2017091865A1 (en) 2015-12-03 2016-12-02 Monitoring treatment or progression of myeloma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021165655A Division JP2022000059A (ja) 2015-12-03 2021-10-07 骨髄腫の治療または進行のモニタリング

Publications (2)

Publication Number Publication Date
JP2018537128A JP2018537128A (ja) 2018-12-20
JP2018537128A5 true JP2018537128A5 (enExample) 2019-12-26

Family

ID=58796005

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018548246A Pending JP2018537128A (ja) 2015-12-03 2016-12-02 骨髄腫の治療または進行のモニタリング
JP2021165655A Pending JP2022000059A (ja) 2015-12-03 2021-10-07 骨髄腫の治療または進行のモニタリング

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021165655A Pending JP2022000059A (ja) 2015-12-03 2021-10-07 骨髄腫の治療または進行のモニタリング

Country Status (8)

Country Link
US (1) US20180282820A1 (enExample)
EP (1) EP3384050A4 (enExample)
JP (2) JP2018537128A (enExample)
KR (1) KR20180088690A (enExample)
CN (1) CN108603232A (enExample)
AU (1) AU2016363113A1 (enExample)
CA (1) CA3007426A1 (enExample)
WO (1) WO2017091865A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
BR112013020220B1 (pt) 2011-02-09 2020-03-17 Natera, Inc. Método para determinar o estado de ploidia de um cromossomo em um feto em gestação
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
RU2760913C2 (ru) 2016-04-15 2021-12-01 Натера, Инк. Способы выявления рака легкого
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3067637A1 (en) 2017-06-20 2018-12-27 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free dna
US11810672B2 (en) 2017-10-12 2023-11-07 Nantomics, Llc Cancer score for assessment and response prediction from biological fluids
CN107881233A (zh) * 2017-10-31 2018-04-06 天津协和华美医学诊断技术有限公司 一种检测骨髓瘤相关基因群的检测试剂盒
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
EP3784805A1 (en) * 2018-04-23 2021-03-03 Inivata Limited Method for predicting and monitoring response to an immune checkpoint inhibitor
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
BR112021002189A2 (pt) 2018-08-08 2021-05-04 Inivata Ltd. método de sequenciamento que usa pcr multiplex de replicação variável
CN113874525A (zh) * 2018-10-29 2021-12-31 分子听诊器公司 使用无细胞信使rna的骨髓表征
WO2020092646A1 (en) * 2018-10-30 2020-05-07 Molecular Stethoscope, Inc. Cell-free rna library preparations
WO2020131955A1 (en) * 2018-12-17 2020-06-25 The Medical College Of Wisconsin, Inc. Assessing risk with total cell-free dna
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
US20210087638A1 (en) * 2019-09-23 2021-03-25 Dana-Farber Cancer Institute, Inc. Next-generation sequencing assay for genomic characterization and minimal residual disease detection in the bone marrow, peripheral blood, and urine of multiple myeloma and smoldering myeloma patients
CN112760290A (zh) * 2019-10-21 2021-05-07 郑州大学 携带突变的肿瘤驱动基因的干细胞及其用途
EP4055187B1 (en) * 2019-11-06 2025-08-20 The Board of Trustees of the Leland Stanford Junior University Methods for analyzing nucleic acid molecules
FR3105738B1 (fr) * 2019-12-26 2024-01-05 P M B Dispositif d’irradiation collaboratif
CN112698037B (zh) * 2021-03-25 2021-06-25 北京积水潭医院 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用
CN116679065B (zh) * 2023-07-31 2023-11-14 北京大学人民医院 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019694A1 (en) * 2008-08-12 2010-02-18 The Ohio State University Research Foundation Micro-rna-based compositions and methods for the diagnosis, prognosis and treatment of multiple myeloma
EP2499486A4 (en) * 2009-11-13 2013-11-27 Infinity Pharmaceuticals Inc COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, EVALUATION, PREVENTION, AND THERAPY OF CANCER
US20150184246A1 (en) * 2011-11-11 2015-07-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
EP4253558B1 (en) * 2013-03-15 2025-07-02 The Board of Trustees of the Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
CA2926722A1 (en) * 2013-10-19 2015-04-23 Trovagene, Inc. Detecting mutations in disease over time

Similar Documents

Publication Publication Date Title
JP2018537128A5 (enExample)
JP2022000059A5 (enExample)
Digumarthy et al. Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?
Jenkins et al. Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non–small cell lung cancer
Rios Velazquez et al. Somatic mutations drive distinct imaging phenotypes in lung cancer
De Mattos-Arruda et al. Cell-free circulating tumour DNA as a liquid biopsy in breast cancer
Ilié et al. Pros: Can tissue biopsy be replaced by liquid biopsy?
Douillard et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status
Haselmann et al. Liquid profiling of circulating tumor DNA in plasma of melanoma patients for companion diagnostics and monitoring of BRAF inhibitor therapy
ES2894479T3 (es) Análisis mutacional de ADN de plasma para la detección de cáncer
JP6480349B2 (ja) 血液でのegfr変異の検査
CN112805563A (zh) 用于评估和/或治疗癌症的无细胞dna
Payne et al. Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma
Mino-Kenudson Cons: Can liquid biopsy replace tissue biopsy?—the US experience
Ghazani et al. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study
Davis et al. Genomic complexity predicts resistance to endocrine therapy and CDK4/6 inhibition in hormone receptor–positive (HR+)/HER2-negative metastatic breast cancer
JP2022516152A (ja) 転移性組織サンプルのトランスクリプトームデコンボリューション
TWI670495B (zh) 一種鑑定樣本中腫瘤負荷的方法和系統
JP2010539490A5 (enExample)
JP2017090158A (ja) 免疫状態の分析のための検査方法
Liang et al. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: correlation with clinical outcomes to EGFR-TKIs
JP2015210268A5 (enExample)
Takahashi et al. CT negative attenuation pixel distribution and texture analysis for detection of fat in small angiomyolipoma on unenhanced CT
Papastefanou et al. Metabolic activity of primary uveal melanoma on PET/CT scan and its relationship with monosomy 3 and other prognostic factors
Wu et al. Prediction of the sarcopenia in peritoneal dialysis using simple clinical information: A machine learning‐based model